Illumina, Inc. (ILMN) Director Sells $1,552,200.00 in Stock

Share on StockTwits

Illumina, Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $310.44, for a total value of $1,552,200.00. Following the completion of the transaction, the director now directly owns 8,256 shares in the company, valued at $2,562,992.64. The sale was disclosed in a legal filing with the SEC, which is available through this link.

ILMN stock traded up $12.83 during trading on Friday, hitting $325.52. The company had a trading volume of 1,163,515 shares, compared to its average volume of 990,358. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. Illumina, Inc. has a 12 month low of $236.71 and a 12 month high of $372.61. The stock has a market capitalization of $46.47 billion, a PE ratio of 56.91, a price-to-earnings-growth ratio of 2.17 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.34 by $0.26. The company had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.45 EPS. As a group, equities analysts expect that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.

Several brokerages have recently commented on ILMN. OTR Global downgraded Illumina to a “positive” rating in a report on Tuesday, April 2nd. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th. Canaccord Genuity restated a “buy” rating and issued a $350.00 price objective (down previously from $360.00) on shares of Illumina in a research report on Friday, April 26th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $340.00 to $370.00 in a research report on Thursday, January 3rd. Finally, BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $353.58.

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc raised its position in shares of Illumina by 1.8% during the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after acquiring an additional 188,516 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of Illumina by 66,581.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock valued at $35,000 after acquiring an additional 10,546,495 shares during the last quarter. Jennison Associates LLC raised its position in shares of Illumina by 13.5% during the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock valued at $1,643,486,000 after acquiring an additional 653,348 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Illumina by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after acquiring an additional 170,046 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Illumina during the 4th quarter valued at $514,627,000. Institutional investors own 90.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Illumina, Inc. (ILMN) Director Sells $1,552,200.00 in Stock” was reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://weekherald.com/2019/05/03/illumina-inc-ilmn-director-sells-1552200-00-in-stock.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Overbought

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.